Open access peer-reviewed chapter

Interferon-Induced Thrombotic Microangiopathy

By Ajay Kundra, Mirela Andrei and Jen Chin Wang

Submitted: May 16th 2017Reviewed: January 19th 2018Published: March 7th 2018

DOI: 10.5772/intechopen.74226

Downloaded: 174


Interferon (IFN) is an effective therapy for multiple disorders. An infrequently reported side effect is thrombotic microangiopathy (TMA): thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS). We published the first comprehensive review analyzing this association with the following observations: (1) there was a higher incidence of IFN-induced TMA in myeloproliferative disorders (chronic myelogenous leukemia (CML)) than that in nonmalignant disorders (multiple sclerosis (MS), chronic hepatitis C virus infection (HCV)); (2) mean age at diagnosis was 47 years; (3) there was rare association with hairy cell leukemia (HCL), Sezary syndrome (one case each) and no cases reported for polycythemia vera (PV); (4) sex distribution was balanced (exception of higher prevalence in females for MS); (5) TMA was insidious in onset with long incubation periods (average treatment duration 40.4 months); (6) comparative analysis of mean time (months) to onset of TMA ensuing cumulative IFN exposure was: MS 68.6 vs. CML 35.5 vs. HCV 30.4; (7) confirmed TTP (low ADAMTS 13 levels) was associated with the presence of an inhibitor; (8) outcome analysis revealed complete remission in 27 (40%), persistent chronic kidney disease in 28 (42%) and fatality in 12 patients (18%); (9) corticosteroids, plasma exchange (PEX) and rituximab are effective therapies.


  • thrombocytopenia
  • interferon
  • thrombotic microangiopathy (TMA)
  • thrombotic thrombocytopenia purpura (TTP)
  • myeloproliferative disorder
  • HCV

1. Introduction

Thrombocytopenia is a common side effect of IFN treatment. TMA is a distinct clinical entity with potentially fatal consequences without precise and expeditious intervention. Classic clinical presentation includes a triad of anemia, thrombocytopenia, and evidence of microangiopathic hemolysis on the peripheral blood smear. The quintessential pathologic feature is the development of microvascular thrombi affecting small or larger vessels with variable organ involvement. TMA, including TTP, is associated with a broad spectrum of conditions such as hemolytic uremic syndrome (HUS), disseminated intravascular coagulation (DIC), malignant hypertension, infections, autoimmune disorders and drugs. Irrespective of etiology, endothelial damage is the fundamental process and is instrumental in the generation of intravascular microthrombi [1]. Furthermore, TTP is characterized by decreased ADAMTS-13 levels, with most patients having severe deficiency (<10%). There was no prior precedent of a comprehensive review exploring IFN-associated TMA. We performed a PubMed search of all articles published between January 1993 and July 2016, focusing on interferon-induced TMA cross-referenced with the following terms: thrombotic thrombocytopenic purpura (TTP), IFN and thrombocytopenia, thrombotic microangiopathies, ADAMTS-13, autoimmune disease and IFN, interferon and hepatitis C, IFN and CML, IFN and multiple myeloma, IFN and renal cell cancer, IFN and polycythemia vera, IFN and lymphoma. Our analysis of this data was published in an exclusive review [2] with results outlined in the following sections.

2. Results

2.1. Age

Majority of patients were between 40 and 60 years of age. Mean ± SE was 47 (95% CI, 44–50). There was no correlation between age and duration of interferon treatment (Figure 1). For comparison of older (≥60 years) to younger (<60 years) patients with regard to the duration of IFN treatment, Mann Whitney U test was used; median and interquartile range (in months) were (28, 5.5–46) and (23.50, 5–60) for older and younger age groups, respectively. Results were not statistically significant (Figure 2).

Figure 1.

Correlation of age to duration of interferon (IFN) treatment before developing TMA. Sixty-eight patients including 29 CML, 20 MS, 17 Hepatitis C, 1 hairy cell leukemia, and 1 Sezary syndrome were studied. Correlation analysis using nonparametric Spearman’s method was used to correlate age and duration of treatment (months). No significant correlation between age and duration of IFN usage was found.

Figure 2.

Comparison between older age (≥60) with younger age (<60) in relation to the duration of IFN usage. In order to compare older (≥60 years) to younger (<60 years) patients with regard to the duration of interferon treatment, Mann Whitney U test was used; median and interquartile range (in months) were (28, 5.5–46) and (23.50, 5–60) for older and younger age groups, respectively. No statistical significance was found.

2.2. Sex

On cumulative data review, for the cases where information was available, sex distribution was balanced (30 male and 33 female patients). In subgroup analysis, patients with MS treated with IFNβ had a female predominance (12 out of 16; 75%). This may, however, just be reflective of higher prevalence of MS in women.

2.3. Associated clinical conditions

An aggregate of 68 cases reported from January 1993 to July 2016 was reviewed. The chronologic distribution of cases of IFN-induced TMA based on underlying diagnosis is shown in Figure 3. Incidence was highest in patients with CML followed by MS and HCV (29, 20 and 17, respectively) [3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44]. One case each was reported in patients with hairy cell leukemia (HCL) and Sezary syndrome [45, 46]. There have been no reports in patients with CML in the last 10 years correlating with the change in standard of care for the treatment of CML with tyrosine kinase inhibitors. There was no apparent difference in age distribution based on diagnosis. The cumulative duration of IFN exposure was highest in patients with MS treated with IFN β when compared to CML or HCV treated with IFN α: mean (months) ± SE: MS 68.6 (95% CI, 45.85–91.4), CML 35 (95% CI, 25.3–45.7) and HCV 12 (95% CI, 0.14–23.94). This was statistically significant (Figure 4) and is probably due to the difference in interferon type or different disease entity (IFNβ in MS vs. IFNα in CML and HCV). Predominant clinical presentation was neurologic dysfunction, anemia, thrombocytopenia, and renal insufficiency. Platelet counts were analyzed for 50 patients where complete blood count (CBC) data were available. Sixteen patients were diagnosed with TTP based on clinical presentation, low ADAMTS13 level, renal biopsy or other evidence of TMA and the remaining as HUS, TTP-HUS or TMA. We grouped the latter for the purpose of our analysis as TMA unspecified. It appears that all patients with TTP presented with moderate-to-severe thrombocytopenia. In the group TMA unspecified, this was not a consistent finding (Figure 5). A significant number of patients were diagnosed as having TMA based on characteristic renal biopsy findings of microangiopathy. There were no other clearly discernible features that set these subgroups of patients apart.

Figure 3.

Incidence of reported cases of thrombotic microangiopathy by year and diagnosis: Results of incidence data analysis from the first reported case of IFN-induced TMA in 1993 to July 2016.

Figure 4.

Comparison of cumulative IFN dose exposure prior to the onset of TMA in patients with CML, Hepatitis C, MS. Patients with MS treated with IFNβ showed longest duration of treatment exposure prior to the onset of TMA in comparison with patients with CML and hepatitis C treated with IFNα. Data were statistically significant.

Figure 5.

Platelet count trend at the time of diagnosis of TTP and TMA unspecified. Out of the 50 patients with available CBC data, 16 were diagnosed as TTP and rest as HUS, TTP-HUS or TMA. Data from the latter group of patients were pooled for the purpose of analysis as TMA unspecified. Patients with TTP presented consistently with moderate-to-severe thrombocytopenia, whereas there were wide fluctuations in platelet counts in patients with TMA unspecified.

2.4. Treatment and outcome

In our review of the 63 patients with available treatment data, 35 (56%) were treated with plasma exchange (PEX) with or without steroids, 12 (19%) were treated with steroids with or without plasma infusion, and 16 (25%) were treated by other means including IFN discontinuation or dose reduction, antihypertensive treatment, rituximab and hemodialysis. Of the 67 patients with available outcome data, 27 patients (40%) had complete response, 28 (42%) developed persistent CKD and 12 (18%) had a fatal outcome (Figure 6).

Figure 6.

Outcome analysis data: Of the 67 patients with available outcome data, 27 patients (40%) had complete response, 28 (42%) developed persistent CKD and 12 (18%) died. Data were shown by underlying diagnosis.

2.5. Role of ADAMTS-13 inhibitor

There were eight cases of TTP where low ADAMTS 13 level was demonstrated, six of these also had ADAMTS 13 inhibitor. Notably, all patients with ADAMTS 13 inhibitor responded to PEX, steroids, and, in resistant cases, rituximab and vincristine. These results imply that IFN-induced TTP is probably an immune-mediated phenomenon with immune suppression being a key therapeutic intervention. ADAMTS13 levels were not available for all other cases making clear distinction between TTP and HUS difficult. We therefore analyzed results under the broader umbrella of TMA. In this context, we used a composite term TTP-HUS for clinical description.

3. Discussion

IFNs are a family of natural cytokines that interfere with viral replication, cell proliferation and immune regulation. Endogenous interferon production constitutes the initial nonspecific immune response against viral infections before specific host immune repertoire takes over. There are two major types of endogenous interferons: type 1 (IFNα—produced by leukocytes; IFNβ—produced by fibroblasts and epithelial cells) and type 2 (IFNγ—produced by activated T cells and NK cells). Viral infection activates pattern recognition receptors such as toll-like receptors (TLR) on macrophages and induces early IFN-1 activation. This further accelerates viral clearance by the upregulation of adaptive immune response [47]. Clinical applications of treatment with exogenous IFN include hematologic malignancies such as CML, lymphoma, PV; solid tumors such as renal cell carcinoma; and nonmalignant disorders such as MS and HCV. Besides CML and one case each of Sezary syndrome and hairy cell leukemia, IFN use has not been associated with TMA in any other myeloid or lymphoid malignancy [46, 48, 49, 50, 51, 52].

In order to understand pathologic process involved, it is important to outline the known and proposed mechanisms of action of IFN. Recombinant type I interferons (α and β) are pleiotropic cytokines that affect cellular function via immune regulatory mechanisms along with the regulation of cellular proliferation, apoptosis and angiogenesis. Dominant mechanisms are also disease specific. For example, in MS, T regulatory cell (Treg) dysregulation and decreased T helper (Th1) activity have been associated with clinical relapses [53]. Also, more recently, immunopathologic response from Th17 expansion and breakdown of blood brain barrier (BBB) have been implicated. Among other mechanisms, recombinant IFNβ is thought to restore Th1/Th2 balance, Treg function and regulation of T cell trafficking across BBB, thereby decreasing neuronal damage.

IFN action in myeloproliferative neoplasms (MPNs) is more complex, is incompletely understood and appears to utilize several pathways. While IFNα is not a Janus kinase 2 (JAK-2) inhibitor, it is able to eliminate the malignant JAK 2 mutant clone and achieve molecular remission in PV. There are a few widely accepted hypotheses for the mechanism of action of IFNα in MPN: enhanced cycling of quiescent leukemic stem cells (LSCs), restoration of dendritic cell function and promoting T cell activation by overcoming T cell energy [54, 55, 56].

Several possible pathophysiologic mechanisms have been described by which IFN may lead to TMA. In our review, cases with a clear diagnosis of TTP (with measured low levels of ADAMTS 13) also had ADAMTS 13 antibodies (ADAMTS 13 inhibitor). It appears that IFN-induced immune response plays a pivotal role in the production of cross-reacting anti-ADAMTS-13 antibodies with resultant microangiopathic hemolysis. While seemingly speculative, this observation has to be seen in the context of association of interferon therapy with the development of other autoimmune diseases. Prospective studies from patients treated with IFNα for hepatitis C showed that approximately 40% patients developed antithyroid antibodies with 15% developing clinical disease [57]. There are three different types of thyroid dysfunction associated with the IFN treatment: autoimmune (often subclinical) hypothyroidism, destructive thyroiditis and Graves hyperthyroidism. Females carry a higher risk to develop autoimmune thyroid disorders (AITDs) upon IFN treatment, with a relative risk of 4.4 (95% CI, 3.2–5.9) [58]. The pattern of thyroid disease observed resembles endogenous immunostimulation in the postpartum period. Development of multiple sclerosis has also been reported following the treatment of chronic phase CML with IFNα2b [59]. Taken together, these observations lend support to our inference that immune activation is fundamental for IFN-induced TTP.

The pathogenesis of TMA may also involve inhibition of vascular endothelial growth factor (VEGF) in renal podocytes [60]. Under physiologic conditions, VEGF stimulates signal transduction pathways and transcription through activation of its receptor VEGFR2. These events are essential for angiogenesis. The physiologic role of VEGF in kidneys is unclear but it has been associated with the pathophysiology of various renal diseases. Renal consequences of VEGF inhibition have been studied for VEGF antagonist bevacizumab. It has been proposed that local production of VEGF plays a critical protective role in microangiopathic processes. VEGF inhibitors such as bevacizumab disrupt this pathway and promote thrombotic microangiopathy [61]. IFN type 1 family also causes VEGF inhibition and hence may have a shared pathogenetic mechanism with VEGF antagonists. Vasoconstrictive and pro-coagulant effects of type I interferon have also been studied in pulmonary arterial hypertension. Experimental models have shown that IFNα increases pulmonary vascular resistance by the activation of thromboxane cascade [62].

There are various mechanisms proposed for IFN-induced HUS. Increased leukocyte adhesion to endothelial cells triggers endothelial damage and releases large multimers of von Willebrand factor causing endothelial swelling, platelet aggregation and intraluminal microthrombi formation causing tissue injury [63]. The development of antiphospholipid antibodies [64], antiendothelial cell antibodies and overexpression of class I antigens rendering cells vulnerable to cytotoxic response are some of the other described mechanisms [65].

Kavanagh et al. described potential immune-mediated and toxic mechanisms of IFN-induced TMA in MS patients [66]. They also reported a cumulative dose-toxicity relationship similar to our observation. In their analysis of data from a single institution involving eight patients, the duration of exposure was similar for IFNα and IFNβ, with TMA developing with long-term therapy at higher doses. In our analysis of a larger patient cohort, however, there is a statistically significant difference between the duration of exposure in MS (treated with IFNβ) versus CML and HCV (treated with IFNα). Although there is a complex interplay of a multitude of factors, our observations suggest that the underlying disease process is a key determinant accounting for the differences in the duration of exposure to IFN preceding onset of TMA. Additionally, however, the differences in IFN subtype (due to the differences in potencies of immunomodulatory and antiproliferative properties) is probably an additional, but secondary factor. In MS, among the accepted underlying mechanisms of IFN action is the ability to regain immunologic balance by restoring Treg cell function. On the other hand, in CML, IFN treatment creates a proinflammatory state for effective immune surveillance. This is supported by the observation of clonal T cell expansion in CML patients treated with IFNα. This difference between immune modulation and immune escalation could possibly account for the earlier development of TMA in CML. Similarly, in treatment of HCV, exogenous IFN binds to cell surface receptors and causes activation of IFN response genes (IRGs) via signal transduction through JAK–STAT pathway. This augments inflammatory response creating an antiviral state [67]. Immune dysfunction is commonly seen in lymphoproliferative disorders wherein the malignant cells originate from the immune system itself. It is therefore possible that impaired autoantibody production in this setting may be the reason for the lack of any observed cases of TMA in lymphoma. Limited clinical indications for IFN use may explain similar finding in PV.

Early diagnosis and prompt institution of treatment is of paramount importance in TMA. In contrast to drug-induced thrombocytopenia, IFN-induced TMA is insidious in onset with long incubation periods (average 40.2 months) and may masquerade as a more benign condition. It is therefore imperative that this association is recognized in clinical practice. Since ADAMTS13 results are not available in real time, a proposed quick guide to determine the likelihood of severely deficient ADAMTS13 activity is PLASMIC score (platelets, lysis, active cancer, stem cell or solid organ transplant, MCV, INR, creatinine): 0–4 score is associated with a low risk of severe ADAMTS13 deficiency, 5 score with intermediate risk and 6–7 scores with high risk [68].

Determining appropriate treatment for drug-associated TMA is challenging. Discontinuation of offending medication is the logical first step. Plasma exchange remains the standard treatment for acquired TTP. That said, since antibodies are present in only a small proportion of drug-associated TMA, the efficacy of plasma exchange in this setting is unclear [66]. A novel upcoming treatment option for patients with acquired TTP is Caplacizumab. This anti-von Willebrand factor (vWF) humanized immunoglobulin blocks vWF-mediated plasma aggregation and showed a 67% reduction in recurrence, 74% reduction in TTP-related death and a trend toward faster normalization of the three organ damage markers: lactate dehydrogenase (LDH), troponin and serum creatinine in the double-blind, placebo-controlled, phase 3 HERCULES trial [69]. These novel strategies may be a harbinger for new, more effective therapeutic options in TTP.

In the past few decades, most of the reported cases of IFN-induced TMA have been associated with CML, MS and chronic hepatitis C. Tyrosine kinase inhibitors are now the treatment standard for CML. Therefore, not surprisingly, there have been no reports of IFN-induced TMA in patients with CML in the last decade. In addition, with the development of more effective antiviral agents, interferon-free regimens for chronic hepatitis C are emerging. Taken together, with diminishing clinical applications of IFN, we may see an overall decrease in the reports of IFN-induced TMA hereon. The last few years, however, have also seen the emergence of immunooncology in cancer therapeutics. Immune checkpoint inhibitors including CTLA-4 antibodies and PD-1 ligands are now approved with expanding clinical applications. These agents potentiate immune response against tumors exponentially by blocking the inhibitory pathways utilized by tumors to escape host immune surveillance mechanisms. Augmentation of host immunity, however, results in breaking self-tolerance and induction of immune-related side effects (ir-AE). Most common side effects are colitis and pneumonitis requiring immune suppression for resolution. Cortazar et al. described a 58-year-old male with melanoma who developed TMA that correlated with treatment with Ipilimumab (CTLA-4 antibody) [70]. This is an interesting observation in the context of our analysis, especially of the mechanisms involved in IFN-induced TMA. It is yet to be ascertained, as we gain more experience with these agents whether this will be an isolated or consistent observation. Nevertheless, it would be prudent to consider the likelihood of these adverse effects in the future.

4. Conclusion

Historically, exogenous IFN (α and β) has been the primary therapy for a variety of diseases such as chronic HCV, chronic phase CML, MS, lymphoma and PV. IFN can trigger autoimmune diseases such as autoimmune thyroiditis. IFN-mediated immune upregulation with the production of cross-reacting antibodies to ADAMTS 13 and complement activation from endothelial injury are the probable pathways for IFN-induced TMA. From our observation, barring differences in time of onset and cumulative dose exposure, the presentation, clinical course and response to treatment appear to be similar among different IFN subtypes and across all indications of use. Treatment regimens utilizing plasma exchange, steroids and rituximab result in durable responses. While interferon may have a myelosuppressive effect causing gradual onset thrombocytopenia, thrombotic microangiopathy, a possible fatal complication should be considered in the differential diagnosis. Once recognized, early institution of appropriate treatment results in favorable outcome. Our analysis also indicates that in patients who had positive ADAMTS13 inhibitors, plasma exchange was a very effective therapy with complete response. Finally, while interferons may have diminishing clinical applications, interferon-induced thrombotic microangiopathy has provided us with valuable lessons pertaining to collateral consequences of immune upregulation. This has resulted in a paradigm shift in our understanding of immunobiology and will have far reaching applications in immunomodulating therapeutics.


Vladimir Gotlieb, MD, Boris Avezbakiyev, MD, Hesham Taha, MD, Brookdale University Hospital Medical Center, Brooklyn, NY, USA.

Conflict of interest


How to cite and reference

Link to this chapter Copy to clipboard

Cite this chapter Copy to clipboard

Ajay Kundra, Mirela Andrei and Jen Chin Wang (March 7th 2018). Interferon-Induced Thrombotic Microangiopathy, Thrombocytopenia, Pankaj Abrol, IntechOpen, DOI: 10.5772/intechopen.74226. Available from:

Embed this chapter on your site Copy to clipboard

<iframe src="" />

Embed this code snippet in the HTML of your website to show this chapter

chapter statistics

174total chapter downloads

More statistics for editors and authors

Login to your personal dashboard for more detailed statistics on your publications.

Access personal reporting

Related Content

This Book

Next chapter

Thrombocytopenia in Liver Transplant

By Gabriela Droc

Related Book

First chapter

Clinical Issues in Women with Inherited Bleeding Disorders

By Ana-Rebeca Jaloma-Cruz, Isaura-Araceli González-Ramos, Diana Ornelas-Ricardo, Clara-Ibet Juárez-Vázquez and Hilda Luna-Záizar

We are IntechOpen, the world's leading publisher of Open Access books. Built by scientists, for scientists. Our readership spans scientists, professors, researchers, librarians, and students, as well as business professionals. We share our knowledge and peer-reveiwed research papers with libraries, scientific and engineering societies, and also work with corporate R&D departments and government entities.

More about us